Background. During systemic inflammation, leucocytes are activated and extravasate into damaged tissue. Activation and recruitment are influenced by different mechanisms, including the interaction of leucocytes with platelets and neutrophil extracellular traps (NET) formation. Here, we investigated the molecular mechanism by which hydroxyethyl starch (HES 130/0.4) dampens systemic inflammation in vivo.
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However, uncontrolled or overshooting activation and recruitment during systemic inflammatory processes may also be harmful and cause severe tissue damage leading to organ failure. 2 3 The initial contact between leucocytes and endothelial cells is mediated by selectins which are expressed on inflamed endothelial cells and interact with their counter receptor P-selectin glycoprotein ligand (PSGL)-1 on leucocytes. 3 After the initial contact, leucocytes roll along the endothelium and collect several activating signals. 3 Chemokines, presented on inflamed endothelial cells, bind to G-protein-coupled receptors on leucocytes and trigger an intracellular signalling cascade leading to integrin activation and leucocyte arrest.
by glycoproteins on activated platelets binding directly or indirectly to integrins on neutrophils. 6 The formation of plateletneutrophil aggregates is required for neutrophil recruitment into organs during systemic inflammation. 10 Recently, it has been demonstrated that intimate platelet -neutrophil interactions induce the formation of neutrophil extracellular traps (NET) under inflammatory conditions. 11 12 During NETosis, neutrophils decondensate and release their nuclear DNA in long chromatin filaments that form extracellular, web-like structures. 13 NETs contribute to the pathology of several inflammatory diseases. 14 -16 The plasma expander hydroxyethyl starch (HES) is frequently used for fluid resuscitation in hypovolaemic patients and has been shown to have anti-inflammatory effects. Previously, HES was demonstrated to reduce neutrophil chemotaxis through monolayers of human umbilical vein endothelial cells (HUVEC), 17 but it did not directly abrogate responses of neutrophils to activating agents. 18 19 Adhesion of flowing neutrophils to HUVEC that had been stimulated with tumour necrosis factor (TNF) a or interleukin-1 (IL-1) was inhibited in the presence of HES, but HES had no effect on the responses of the HUVEC to these cytokines, in terms of adhesion molecule expression. 19 -21 Furthermore, in vitro experiments showed that HES does not inhibit adhesion per se, but modified the recruitment by endothelial cells in a differential manner, depending on TNF-a dose, attributable to changes in selectin or chemokine expression at low or high dose, respectively. However, the effect of HES (130/0.4) on leucocyte recruitment and inflammation has not been investigated in vivo.
The aim of the present study was to investigate the molecular mechanism by which HES 130/0.4 influences neutrophil recruitment and inflammation during systemic inflammation.
Methods

Animals
We used 8-to 12-week-old male C57BL/6 mice. The mice were kept in a barrier facility under specific pathogen-free conditions. All animal experiments were approved by local government authorities, followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and relevant sections of the ARRIVE guidelines.
Reagents
Unlike otherwise stated, all reagents were obtained from Sigma-Aldrich (Taufkirchen, Germany).
Murine model of systemic inflammation
Systemic inflammation was induced by caecal ligation and puncture (CLP). Mice were anaesthetized by intraperitoneal injection of ketamine (125 mg g 21 body weight; Pfizer, New York, NY, USA) and xylazine (12.5 mg g 21 body weight; Bayer, Leverkusen, Germany). Sufficient anaesthesia for the analgesic tolerance of surgical procedures was assured using the pedal withdrawal response to a nociceptive stimulus. Animals were killed by exsanguination through transcutaneous cardiac puncture under anaesthesia after the experiment. CLP was performed as described before. 22 Briefly, a midline laparotomy incision was made after skin disinfection. The caecum was ligated 14 mm distal to the ileocecal valve so that continuity was preserved and then punctured twice with a 20 G needle. It was returned to the peritoneal cavity, and the wound was closed in two layers. Mice were then allowed to recover and had free access to food and water. ). Animals were randomized to treatment groups and the investigators were blinded to these groups. An animal group size of eight mice was analysed for each condition. Colony forming units (CFUs) in the lung, blood, and spleen 24 h after CLP were analysed as described previously. 23 
PMN recruitment into different organs
Four, 8, 12 , and 24 h after CLP, mice were killed and perfused with 20 ml phosphate-buffered saline (PBS) via the right and left ventricle. The lung, liver, and kidneys were removed, followed by mechanical tissue homogenization and digestion with collagenase and hyaluronidase at 378C for 60 min. Neutrophils were analysed by flow cytometry (BD FacsCanto; Becton Dickinson, Heidelberg, Germany) based on the expression of CD45 (clone 30-F11, BD Biosciences, Franklin Lakes, NJ, USA), GR-1 (clone RB6-8C, 5 purified from hybridoma supernatant), and Ly6B.2 (clone 7/4, AbD Serotec, Dü sseldorf, Germany). FACS data were processed using FlowJo (version 7.5.5; Tree Star, Inc., Ashland, OR, USA).
Intravital microscopy of the cremaster and kidney
To investigate the influence of HES 130/0.4 administration on leucocyte recruitment during systemic inflammation in vivo, we performed intravital microscopy (IVM) of the cremaster muscle and kidney as described previously. 24 -27 PMN capturing and chemokine-induced neutrophil arrest in vitro
To investigate neutrophil capturing and chemokine-induced arrest, we used a whole blood-perfused murine microflow chamber system as described previously. 24 26 Murine whole blood was withdrawn from the left ventricle into a heparinized syringe from mice which had received an i. 
Quantification of platelet-neutrophil aggregates
The amount of platelet -neutrophil aggregates in murine blood in vivo was determined as described previously. 10 For 60 the quantification of platelet -neutrophil aggregates in vitro, isolated washed platelets were stimulated with thrombin (0.1 units ml 21 ) at 378C for 5 min and mixed with bone marrowderived leucocytes obtained from wild-type mice. The reaction was stopped with the addition of 400 ml ice-cold PBS and the samples were incubated with CD45-PerCP antibody (clone 30-F11), CD41-PE antibody (clone MWReg30), Ly-6B.2-FITC antibody (clone 7/4), and Gr1-antibody (clone RB6-8C5) conjugated with Alexa633 for 10 min. Samples were analysed on a FACSCanto flow cytometer (BD Biosciences). FACS data were processed using FlowJo (version 7.5.5; Tree Star, Inc.).
Statistical analysis
The power analysis on the required group size, which was performed before initiating the experiments, was performed with G*Power software (G*Power 3.1.7 by Axel Buchner, University of Duesseldorf, Germany). Statistical analysis was performed with SPSS (version 21.0) using the Wilcoxon test or t-test as appropriate. More than two groups were compared using one-way analysis of variance followed by the Bonferroni testing. Data distribution was assessed using the KolmogorovSmirnov test or Shapiro -Wilks test. All data are represented as mean and SD. A P-value of ,0.05 was considered as statistically significant. See Supplementary material for further information.
Results
HES 130/0.4 reduces leucocyte adhesion and transmigration during systemic inflammation after CLP in vivo.
The administration of HES130/0.4 did not change the number of neutrophils interacting with the endothelial cells ('rolling flux fraction') and the rolling velocity under noninflammatory and inflammatory condition (Fig. 1A and B) . Animals treated with HES 130/0.4 or control solution had the same number of intravascular adherent leucocytes (Fig. 1C ) and transmigrated leucocytes (Fig. 1D ) in post-capillary venules of the cremaster muscle after sham operation. However, IVM of the cremaster muscle revealed a significant increase in the number of adherent (Fig. 1C ) and transmigrated leucocytes ( Similar to the IVM of the cremaster muscle, IVM of the kidney revealed a significant increase in the number of intravascular adherent leucocytes in the cortical venules of the kidney during systemic inflammation (Fig. 1E) . The administration of HES 130/0.4 significantly decreased the number of adherent leucocytes compared with mice which received the control solution (Fig. 1E) .
To exclude the possibility that the systemic inflammation significantly reduces arterial blood pressure, which might alter perfusion of the microcirculation and subsequently reduces neutrophil recruitment, we measured the systolic arterial blood pressure in control mice and mice suffering from systemic inflammation. The arterial blood pressure in these groups was not different (Supplementary Fig. S1 ). To exclude the possibility that the application of HES 130/0.4 at doses of 20 ml kg 21 over a period of 1 h, a dose similar to that used in patients, causes adverse haemodynamic effects in mice or increases vascular permeability, we measured the systolic arterial blood pressure and lung wet/dry ratio in control mice after administration of HES 130/0.4 over 1 or 2 h. There was no difference in systolic arterial blood pressure or lung wet/dry ration between the groups, indicating that HES 130/0.4 administration at 20 ml kg 21 over 1 h does not alter the systolic arterial blood pressure or vascular permeability ( Supplementary Fig. S1 ).
HES 130/0.4 does not affect neutrophil capturing, but reduces chemokine-induced neutrophil arrest in vitro
In order to analyse whether HES 130/0.4 affects neutrophil capturing, we performed flow chamber assays. Neutrophils in whole blood from animals treated with HES 130/0.4 and control solution showed the same number of rolling neutrophils on P-selectin ( Fig. 2A) . To investigate neutrophil rolling, we coated the flow chambers with either P-selectin and ICAM-1 or P-selectin alone. Neutrophils from mice treated with HES 130/0.4 or the control solution had the same rolling velocity on P-selectin alone (Fig. 2B) . HES 130/0.4 did not influence the rolling velocity on P-selectin and ICAM-1 compared with the control solution (Fig. 2B) . During capturing and rolling on inflamed endothelial cells, neutrophils are exposed to chemokines which cause firm arrest. To investigate a possible effect of HES 130/0.4 on chemokine-induced arrest, flow chambers were coated with P-selectin/ICAM-1/CXCL-1 or P-selectin/ ICAM-1 as a control. In the absence of CXCL-1, only a low number of neutrophils adhered in the flow chambers perfused with whole blood from HES 130/0.4 or control-treated animals (Fig. 2C) . However, neutrophil adhesion to P-selectin/ICAM-1/ CXCL-1 was significantly reduced in mice with HES 130/0.4 compared with mice treated with the control solution (Fig. 2C) .
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HES 130/0.4 influences the release of inflammatory mediators during systemic inflammation
The plasma levels of the pro-inflammatory mediators CXCL1, CXCL2, IL-6, and HMGB-1 significantly increased during the course of the systemic inflammation ( Fig. 3A-D) . The application of HES 130/0.4 significantly reduced the plasma levels of the pro-inflammatory mediators CXCL1, CXCL2, IL-6, and HMGB-1 (Fig. 3A-D) .
HES 130/0.4 influences neutrophil recruitment during systemic inflammation
The induction of systemic inflammation caused the recruitment of neutrophils into the lung and liver as early as 8 h and into the kidney 12 h after inducing systemic inflammation ( Fig. 4A-C) . After inducing systemic inflammation, the administration of HES 130/0.4 significantly reduced the number of recruited neutrophils in the lungs after 8 h (Fig. 4A ) and in the liver and kidney after 12 and 24 h (Fig. 4B and C) . The administration of HES 130/0.4 after induction of systemic inflammation significantly reduced histological lung injury score (Fig. 4D ) and serum creatinine levels (Fig. 4E) . However, it did not affect hepatic (Fig. 4F ) tissue damage. In order to address the haemodynamic effects of HES and the crystalloid control solution, we analysed heart rate, systolic arterial blood pressure, haematocrit, and serum lactate 24 h after the induction of systemic inflammation. Neither the haematocrit nor global haemodynamic variables (heart rate, systolic arterial blood pressure) were significantly different between the groups (Supplementary Fig. S2 ). In order to investigate the effect of HES on pathogen clearance, animals were killed 24 h after induction of systemic inflammation and we analysed the number of CFUs in the blood, lung, and spleen. The administration of HES 130/0.4 significantly increases the number of CFUs in the spleen and lung (Fig. 5A -C) . HES 130/0.4 reduces the formation of circulating platelet-neutrophil aggregates and NET formation
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As formation of platelet -neutrophil aggregates is known to be involved in systemic and pulmonary inflammation, 6 10 28 we investigated whether the administration of HES 130/04 after inducing systemic inflammation modulates this cell -cell interaction. During systemic inflammation, the number of platelet -neutrophil aggregates significantly increased (Fig. 6A) . The administration of HES 130/0.4 reduced the number of circulating platelet-neutrophil aggregates at 4, 8, 12, and 24 h after inducing systemic inflammation compared with mice treated with the control solution (Fig. 6A) . Similar to these findings, the pretreatment of platelets, but not neutrophils, with HES 130/0.4 also significantly reduced the formation of platelet -neutrophil aggregates in vitro (Fig. 6B) .
The interaction of platelets with neutrophils is known to induce NET formation in vivo. 11 12 To investigate a possible effect of HES 130/0.4 on NET formation, we analysed soluble NET components in the blood 8 h after inducing systemic inflammation or sham operation. Systemic inflammation led to a significant increase in soluble NET components in the blood compared with control mice (Fig. 6C) . HES 130/0.4 significantly reduced soluble NET components in the blood after inducing systemic inflammation compared with the control solution (Fig. 6C ). In addition, NET immunostaining in tissue sections from the lung, liver, and kidney was decreased in HES 130/ 0.4-treated animals after inducing systemic inflammation compared with mice treated with the control solution (Fig. 6D ). Similar to platelet-neutrophil aggregate formation, the pretreatment of platelets, but not neutrophils, with HES 130/0.4 significantly reduced NET formation in vitro (Fig. 6E) .
Discussion
This study demonstrates that HES 130/0.4 reduces inflammation by decreasing the number of platelet -neutrophil aggregates, NET formation, and leucocyte recruitment into different organs during systemic inflammation induced by CLP in mice. These results suggest that HES 130/0.4 has antiinflammatory effects caused by different mechanisms. Leucocyte recruitment into inflamed tissue proceeds in a cascade-like fashion.
3 Disturbing one step of this adhesion cascade reduces leucocyte recruitment, which can be beneficial in the context of ischaemia/reperfusion injury and abacterial inflammation 27 or harmful during bacterial infection. 29 In vitro studies demonstrated that the administration of HES reduces neutrophil adhesion to endothelial cells in flow chamber assays. 19 -21 In addition, HES has been demonstrated to increase cardiac index and improve microcirculation, in part via increased oxygen delivery due to increased plasma colloid oncotic pressure and viscosity during haemorrhagic shock, which might limit endothelial inflammation. 33 This may have also contributed to the decreased neutrophil activation in our study. Platelets play an important role in many inflammatory conditions, 6 and it has been shown that the interaction of platelets with neutrophils is important for neutrophil recruitment into the lung 6 10 28 34 and kidney 35 and for NET formation. 11 12 Eliminating platelets or reducing the interaction of platelets with neutrophils diminishes inflammation and neutrophil recruitment. 10 28 35 During systemic inflammation, the administration of HES 130/0.4 reduced the number of plateletneutrophil aggregates and NET formation. Platelet -neutrophil aggregate formation requires the interaction of distinct surface adhesion molecules on both platelets and neutrophils. 6 Binding of HES to cell surface receptors 32 may reduce the functionality of these receptors and subsequently reduce the formation of the aggregates. Our in vitro data indicate that HES primarily reduces aggregate formation by affecting the platelets. Furthermore, NET formation, which relies on the interaction between platelets and neutrophils under different inflammatory conditions, 11 12 was also reduced as a consequence of the reduced formation of platelet -neutrophil aggregates caused by HES 130/0.4. NETs may activate endothelial cells and subsequently contribute to the regulation of vascular permeability and leucocyte recruitment. 11 However, no research on the effect of HES on NET formation has been published to date. Thus, this is the first study to demonstrate that the administration of HES 130/0.4 reduces NET formation in vivo. Importantly, we also demonstrated that while neutrophil recruitment and NET formation were decreased after HES administration, the number of CFUs in the blood, lung, and spleen was increased in these animals. These data suggest that HES administration leads to increased bacterial growth and dissemination, probably through modulating systemic inflammation and host defence. Another important finding of this in vivo study is that the administration of HES 130/0.4 after inducing systemic inflammation by CLP significantly reduced the blood concentrations of different pro-inflammatory mediators (CXCL1, CXCL2, IL-6, and HMGB-1). These results are in line with studies showing that the administration of HES reduced the production of pro-inflammatory mediators in an in vivo model of endotoxaemia mediated by preventing LPS-induced NF-kB activation. 36 37 Accordingly, blocking neutrophil recruitment 38 and the formation of platelet -neutrophil aggregates 39 also reduces the concentration of pro-inflammatory cytokines in the blood. This study has several limitations. The use of HES in critically ill patients with sepsis and septic shock has recently been shown to be associated with an increased risk of renal dysfunction and renal replacement therapy. 40 The European Medicines
Agency does not recommend the use of HES as a resuscitation fluid in patients with sepsis. Thus, it remains a matter of current debate to gauge the impact of the effects of HES on leucocyte recruitment and organ injury during systemic inflammation. In summary, the data from this study show that the administration of HES 130/0.4 during systemic inflammation modulates inflammation by reducing the number of platelet -neutrophil aggregates, NET formation, and leucocyte recruitment into different organs.
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